RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:52416

Mantle cell lymphoma

medium confidenceDisorder

Also known as: LCM · MCL · Mantle zone lymphoma

Publications

22,712

99th percentile

Trials

716

Interventional, condition-specific

Researchers

1,456

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

Mantle cell lymphoma is a rare form of malignant non-Hodgkin lymphoma affecting B lymphocytes in the lymph nodes in a region called the ``mantle zone''.

How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (3)

classical mantle cell lymphoma · mantle cell lymphoma · mantle zone lymphoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    22,712 matched papers (14,247 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    716 matched on ClinicalTrials.gov (114 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

22,712

22,712 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

22,712 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

14,247 in the last 10 years · medium confidence · 99th percentile (publications denominator)

Phrase hits: 22,707 · MeSH hits: 62

Open Europe PMC search

Who's working on it?

1,456

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Wang Y9 papers · 2026

    Department of Pharmacology, Liaoning Key Lab of Targeting Drugs for Hematological Malignancies, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China.

    Papers in Europe PMC
  2. 02
    Ladetto M8 papers · 2026

    Division of Hematology Antonio e Biagio e Cesare Arrigo Hospital Alessandria Italy.

    Papers in Europe PMC
  3. 03
    Wang M8 papers · 2026

    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. miwang@mdanderson.org.

    Papers in Europe PMC
  4. 04
    Eyre TA7 papers · 2026

    Haematology and Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, UK.

    Papers in Europe PMC
  5. 05
    Zhang W7 papers · 2026

    Department of Hematology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

    Papers in Europe PMC
  6. 06
    Zhang Y7 papers · 2026

    Department of Life Sciences, Bengbu Medical University, Bengbu, Anhui, China.

    Papers in Europe PMC
  7. 07
    Dreyling M6 papers · 2026

    Department of Medicine III LMU Hospital Munich Germany.

    Papers in Europe PMC
  8. 08
    Jing H6 papers · 2026

    Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China.

    Papers in Europe PMC
  9. 09
    Liu Y6 papers · 2026

    Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China.

    Papers in Europe PMC
  10. 10
    Wang J6 papers · 2026

    Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

716

interventional trials for this specific condition

716 interventional trials matched this specific condition name; 114 currently recruiting in our sample.

Data as of 27 July 2026

716 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 99.8th percentile).

medium confidence · 99.8th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

716 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

48 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Mantle cell lymphoma" OR "Mantle zone lymphoma" OR "classical mantle cell lymphoma"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Lymphoma, Mantle-Cell

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Mantle cell lymphoma" OR "Mantle zone lymphoma" OR "classical mantle cell lymphoma" OR "Lymphoma, Mantle-Cell"

Interventional trials matched via: both, phrase, mesh (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 716 interventional · 48 observational · 4 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: LCM; MCL

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 2 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T00:48:35.097Z